Ernexa Therapeutics Inc.
ERNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -219,700% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -575,900% |
| EPS Diluted | -0.15 | -0.61 | -0.15 | -0.42 |
| % Growth | 75.4% | -306.7% | 64.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |